Results 131 to 140 of about 9,514 (200)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia. [PDF]

Eur J Med Res
Shu W, Yang Q, He D, Li Y, Le J, Cai Q, Dai H, Luo L, Chen B, Gong Y, Jin D.   +10 more
europepmc   +1 more source

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal. [PDF]

Leukemia
Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Steffens Reinhardt L, Lawlor-O'Neill C, Roper EA, Humphries S, Murray HC, Mannan A, Dun MD, de Bock CE, Bowden NA, Enjeti AK, Verrills NM, Riveros C, Lê Cao KA, Lee HJ.   +18 more
europepmc   +1 more source

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis. [PDF]

Cancers (Basel)
Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T.   +13 more
europepmc   +1 more source

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study. [PDF]

Br J Haematol
Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E.   +26 more
europepmc   +1 more source

Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world study. [PDF]

Blood Neoplasia
Lachowiez CA, Smith BD, Ambinder AJ, Binder G, Angiolillo A, Potluri R, Papademetriou E, LeBlanc TW.   +7 more
europepmc   +1 more source

Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes. [PDF]

Ann Hematol
Sanz-Solas A, Saiz-Rodríguez M, Simal SC, Rodríguez-Veiga R, Solana-Altabella A, Montesinos P, Labrador J.   +6 more
europepmc   +1 more source

The Effectiveness of Hypomethylating Agents in Elderly Patients With Acute Myeloid Leukemia: Insights From a Single-Center Experience. [PDF]

Cureus
Negotei C, Mitu I, Stanca O, Angelescu S, Lapadat ME, Barta C, Berbec NM, Colita A.   +7 more
europepmc   +1 more source

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study. [PDF]

Blood Cancer J
Wurm S, Moritz JM, Petzer V, Wolf D, Gleixner KV, Sperr WR, Groiss C, Machherndl-Spandl S, Eisenwort G, Koller E, Schoeche J, Petrasch C, Singer J, Mayer DM, Pregartner G, Heine A, Wölfler A, Sill H, Reinisch A, Zebisch A.   +19 more
europepmc   +1 more source

Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Ann Hematol
Lee BJ.
europepmc   +1 more source

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents. [PDF]

Am J Hematol
Marconi G, Petracci E, Lanzarone G, Vetro C, Martelli MP, Papayannidis C, Audisio E, Minetto P, Riva C, Guolo F, Martini G, Zappasodi P, Vincenzo F, Gigli F, Griguolo D, Rondoni M, Ciotti G, Borlenghi E, Ciccone N, Palumbo FE, Nanni J, Mattei D, Bernardi M, Cignetti A, Zingaretti C, Vertogen B, Cerchione C, Lanza F, Cilloni D, Brunetti L, Palmieri R, Curti A, Giannini MB, Todisco E, AVALON research group, Fracchiolla N, Martinelli G.   +36 more
europepmc   +1 more source